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Abstract: Spirotetronate and spirotetramate natural products include 
a multitude of compounds with potent antimicrobial and antitumor 
activities. Their biosynthesis incorporates many unusual biocatalytic 
steps, including regio- and stereo-specific modifications, cyclizations 
promoted by Diels-Alderases, and acetylation-elimination reactions. 
Here we focus on the intriguing acetate elimination catalyzed by 
AbyA5, implicated in formation of the key Diels-Alder substrate to give 
the spirocyclic system of the antibiotic abyssomicin C. Using synthetic 
substrate analogues we show that AbyA5 catalyzes stereospecific 
acetate elimination, establishing the (R)-tetronate acetate as a 
biosynthetic intermediate. The X-ray crystal structure of AbyA5, the 
first of an acetate eliminating enzyme, reveals a deviant acetyl 
esterase fold. Molecular dynamics simulations and enzyme assays 
demonstrate use of a His-Ser dyad to catalyze either elimination or 
hydrolysis, via disparate mechanisms, under substrate control.  
Acetylation is a ubiquitous chemical modification of major 
importance in biology. Acetylation state impacts protein stability, 
folding and localization, central metabolism, apoptosis, 
transcription, cytoskeletal organization, circadian regulation, 
bacterial cell wall architecture and integrity, natural product 
bioactivity, and antimicrobial resistance amongst others.[1] The 
addition or removal of acetyl groups is facilitated by the 
coordinated action of acetylases and deacetylases, which 
function within stringently regulated cellular networks.[2] 
Deacetylases have been the subject of considerable detailed 
investigation, and have been shown, without exception, to 
catalyze hydrolysis of the acetate via attack on the carbonyl 
group.[3] Recently, studies of spirotetronate and spirotetramate 
biosynthetic pathways have revealed an alternative biocatalytic 
route to the processing of acetylated molecules. This involves the 
action of free-standing acetate lyases; enzymes which employ a 
hitherto uncharacterized mechanism to eliminate acetate with 
formation of a double bond (Scheme 1).[4] These enzymes are 
unique to spirotetronate/spirotetramate pathways, sharing <20% 
sequence identity to any protein of known structure. Given the role 
of acetate lyases in the biosynthesis of natural products of 
outstanding clinical potential, their enigmatic enzymology, and 
their potential utility as industrially relevant biocatalysts, these 
enzymes represent intriguing and important targets for detailed 
study.    
 
Scheme 1. Enzyme catalyzed deacetylation and acetate 
elimination. 
 
To elucidate the mechanistic details of enzyme catalyzed 
acetate elimination we focused on the putative acetate lyase 
AbyA5 from the abyssomicin C biosynthetic pathway. The 
antimicrobial natural product abyssomicin C (1) is a potent 
inhibitor of bacterial folate metabolism effective against a 
multitude of Gram-positive pathogens including Mycobacterium 
tuberculosis and multi-drug resistant strains of Staphylococcus 
aureus.[5] The biosynthetic pathway to this compound, which 
comprises a multi-modular polyketide synthase (PKS) and 
associated tailoring and regulatory proteins, is encoded for within 
a single gene cluster (aby) spanning ~60 kb of the genome of the 
marine actinomycete Verrucosispora maris AB-18-032.[6] Based 
on feeding studies, chemotyping of V. maris gene knock-out 
mutants, comparative bioinformatics analyses, and in vitro 
studies of homologous enzymes from other spirotetronate and 
spirotetramate pathways, a general mechanism for the 
biosynthesis of abyssomicin C has been proposed (Figure S1).[7] 
One of the most intriguing features of this pathway is the 
formation and subsequent tailoring of the tetronate ring 
containing compound 2, via the acetylated intermediate 3, to yield 
4, which subsequently serves as a substrate for a Diels-Alderase 
catalyzed intramolecular [4 + 2] cycloaddition reaction (Figure 
1).[8] The conversion of 3 to 4 is postulated to proceed via 
elimination of acetate, yielding the 14,15-exocyclic double bond, 
but it is not known which enantiomer of 3 is involved. The 
introduction of this dienophile is implicitly required for the 
subsequent AbyU catalyzed cycloaddition reaction that forms the 
heterobicyclic ring nucleus of abyssomicin C. 
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Figure 1. Tetronate ring formation and tailoring during 
abyssomicin C biosynthesis. 
 
Amino acid sequence alignments of the known 
spirotetronate/spirotetramate acetate lyases Agg5 
(agglomerin)[4b] and QmnD4 (quartromicin),[4a] and putative 
acetate eliminating enzymes from related biosynthetic pathways, 
with Open Reading Frames within the aby cluster, identify AbyA5 
as the likely eliminating enzyme from the abyssomicin C pathway 
(Figure S2). To ascertain whether AbyA5 does indeed catalyze 
acetate elimination, this enzyme was recombinantly over-
expressed in E. coli BL21(DE3) cells and purified to homogeneity 
(Figure S3). Recombinant AbyA5 was found to be a monomeric, 
well-folded, mono-disperse species in solution.  
Both enantiomers of the unnatural substrate analogues of 
acetate 3 were synthesized. Hydroxy ester 5 was readily prepared 
from D-mannitol diacetonide in 4 steps according to the 
literature.[9] Coupling with β-ketothioester 6 in the presence of 
CF3CO2Ag gave keto ester 7 in 79% yield. The key TBAF 
mediated Dieckmann cyclization has wide precedent in the 
literature, however, difficulty has been reported using this 
method.[10] In our hands this reaction proved challenging until the 
purified compound was washed with 1 M HCl according to Osada 
et. al.[11] Following the cyclization the primary alcohol 8 was 
acetylated to give desired (R)-analogue (R)-9. To prepare a 
standard of the elimination product 10 for the enzyme assays, 
acetate (R)-9 was reacted with DBU giving alkene 10, other bases 
(eg. TBAF, imidazole and triethylamine) gave no reaction. An 
alternative approach to the synthesis of 10 is from 11 as shown in 
Scheme 2.  
Incubation of (R)-acetate (R)-9 with recombinant AbyA5 in 
vitro yielded a single product with a mass (m/z [M-H]- = 237) and 
1H-NMR in keeping with alkene 10, and consistent with the 
authentic synthetic standard (Figures 2 and S4), confirming that 
elimination had taken place. Control reactions lacking enzyme, or 
containing heat denatured AbyA5, showed no evidence of product 
formation. AbyA5 showed no activity against the (S)-enantiomer 
(S)-9, demonstrating that the enzyme is stereospecific for the (R)-
form only. Steady-state kinetic characterization of AbyA5 with (R)-
9, employing a spectrophotometric assay (supplementary 
information), yielded kcat= 1.8 ± 0.13 min-1, Km= 27 ± 8.4 μM, and 
kcat/Km= 0.072 ± 0.021 min-1μM (Figure 2). Together these data 
demonstrate the eliminating activity of AbyA5, unambiguously 
establish the role of this enzyme in abyssomicin C biosynthesis, 
and reveal that this reaction proceeds in a stereospecific manner. 
 
 
 
 
Scheme 2. Synthesis of acetate elimination precursor (R)-9 and product 10. MS = molecular sieve, THF = tetrahydrofuran, TBAF = 
tetrabutylammonium fluoride, DMAP = 4-(dimethylamino)pyridine, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, LDA = lithium 
diisopropylamide, DMP = Dess-Martin periodinane, DMSO = dimethylsulfoxide. 
         
 
 
 
 
 
Figure 2. Acetate eliminating activity of AbyA5. a) Synthesized 
substrate analogues (R)-9 and (S)-9 and alkene 10. b) HPLC-MS 
demonstrating the AbyA5 catalyzed conversion of (R)-9 to 10 by 
AbyA5. c) Steady-state kinetic characterization of the conversion 
of (R)-9 to 10. Error bars are standard errors from the mean 
calculated from reactions run in triplicate. 
 
To provide a structural framework of the AbyA5 catalyzed 
elimination reaction we determined the X-ray crystal structure of 
the enzyme. This was achieved using the single wavelength 
anomalous dispersion (SAD) method, to 2.3 Å resolution, 
employing a selenomethinone labeled quadruple point mutant of 
AbyA5, within which the residues Leu66, Leu158, Leu195 and 
Leu295 were mutated to methionines (supplementary 
information). This structure was subsequently used as a 
molecular replacement search model to determine that of wild 
type AbyA5 to 2.5 Å resolution. The structure of AbyA5 is 
consistent with a monomeric α/β hydrolase (ABH), possessing a 
central, largely parallel 8-stranded β-sheet surrounded by α-
helices (Figure 3). As with other ABHs, the second strand within 
the β-sheet runs antiparallel to the remaining 7 and the sheet 
possesses a left handed super-helical twist. The major structural 
features that distinguish AbyA5 from other ABHs are the large 
number of helices that decorate the central β-sheet core of the 
enzyme (15 in total) and the presence of a 4-helix subdomain that 
extends outwards from the top of AbyA5 in a fashion analogous 
to that reported in 2,6-dihydroxy-pseudo-oxynicotine 
hydrolase.[12] Structurally, AbyA5 is most closely related to 
members of the acetyl esterase family of deacetylases, despite 
minimal amino acid sequence identity (<20%). Inspection of the 
AbyA5 crystal structure and superposition with structurally related 
acetyl esterases unambiguously identifies the location of the 
enzyme active site, which sits within an extended cleft on the 
surface of the enzyme of ~40 Å in length and ~10 Å in depth. The 
left side of the cleft houses a canonical ABH catalytic triad, 
comprised of the residues Ser198, Asp285 and His312 (Figure 3). 
Ser198 is located on a nucleophilic elbow formed by a loop linking 
β5 and α7. His312 sits on the opposite side of Ser198, on a loop 
between β8 and α14, directly above Asp285.  
 
 
Figure 3. Crystal structure of AbyA5. a) Overall fold of the AbyA5 
monomer showing the catalytic domain (blue) and 4 helix capping 
domain (yellow). S, Ser198; D, Asp 285; H, H312; b) Active site 
cleft on the enzyme surface (red). The capping domain has been 
removed for clarity. Asp285 is obscured by His312. c) Model of 
(R)-3 and (S)-3 docked into the active site of AbyA5.  
 
Time (mins) 
         
 
 
 
 
To further investigate the acetyl elimination by AbyA5, a 
modelling study was performed. Molecular docking was 
conducted using the AbyA5 crystal structure with both (R)-3 and 
(S)-3. This yielded a series of closely related models of the 
AbyA5-substrate complex, each of which positions the substrate 
directly within the AbyA5 active site cleft and locates the acetyl 
group in close proximity to Ser198 and His312 (Figure 3). The 
side chain of 3 occupies a largely hydrophobic portion on the right 
of the active site cleft. Given the minimal number of contacts 
between AbyA5 and substrate in this region it appears unlikely 
that chain length and composition is a major determinant of 
substrate selectivity. This is consistent with our in vitro assay data, 
which demonstrate that the substrate analogue (R)-9, which lacks 
the side chain functional group decoration of 3, is readily acted 
upon by the enzyme. In contrast, appropriate positioning of the 
acetylated tetronate ring within the active site appears to play a 
significant role in substrate binding. This is achieved by a 
combination of shape and charge complementarity between the 
acetylated ring and the active site cavity, supported by a several 
hydrogen bonds. The point mutants AbyA5_H321A and Ser198A 
showed no activity with (R)-9, despite both proteins being well 
folded monodisperse species in solution (Figure S5), implying a 
critical role for these residues in substrate positioning and/or 
catalysis within the active site. Molecular dynamics simulations 
using docked poses of (R)-3 reveal a distance of ~3.5 Å between 
His312 and C15 of the substrate, optimal for proton abstraction 
and consistent with the His dependent catalytic mechanism 
proposed previously for QmnD4 (Figure S6).[4a] The distance 
between His312 and C15 for (S)-3 docked poses is >4.5 Å, 
sufficient to preclude proton abstraction and thereby negate 
catalysis (Figure 3). Together, these data offer an explanation for 
the stereoselectivity of AbyA5 observed our in vitro enzyme 
assays.  
The crystal structure of AbyA5 raises the intriguing 
possibility that this protein scaffold could support both acetate 
elimination and hydrolysis, though no (R)-9 hydrolytic product 8 
was detected in our functional assays. To test this hypothesis the 
ability of AbyA5 to deacetylate p-nitrophenolacetate (p-NPA) in 
vitro was monitored spectrophotometrically.[13] AbyA5 was found 
to catalyze the hydrolytic deacetylation of p-NPA, with kcat= 44 ± 
2.4 min-1, Km= 78 ± 9.2 μM, and kcat/Km= 0.62 ± 0.31 min-1μM 
(Figure S7). Molecular dynamics simulations of AbyA5 in the 
absence of substrate reveal appropriate positioning of the His-
Ser-Asp triad, as defined by the occupation of hydrogen bonds 
between these side chains, for ~10% of the simulation duration, 
consistent with the ability of the enzyme to catalyze ester bond 
cleavage via a canonical acetyl esterase mechanism (Figure 
S8).[14] The infrequent adoption of this catalytically competent 
state accounts for the comparatively poor catalytic efficiency of 
AbyA5 for p-NPA as compared to naturally evolved acetyl 
esterases, with an up to 60 fold lower kcat/Km (Table S2). Neither 
AbyA5_H321A nor Ser198A showed any activity with p-NPA. 
Docking studies confirmed that p-NPA can be readily 
accommodated within the AbyA5 active site. 
In summary, we report the structural and functional 
characterization of the acetate lyase AbyA5, revealing the 
molecular details of the acetate elimination reaction catalyzed by 
this enzyme, and in doing so, establish explicitly the role of this 
biocatalyst in abyssomicin C biosynthesis. AbyA5 is shown to 
possess an acetyl esterase like fold, within which conserved 
catalytic machinery can be deployed to facilitate either acetate 
elimination or ester hydrolysis, in a manner dictated by substrate 
identity. Our studies establish the origins of substrate selectivity 
in AbyA5, revealing absolute stereoselectivity for the (R)-
tetronate, but relaxed selectivity for the C3 chain. These findings 
hint at the potential general utility of AbyA5 as an acetate 
elimination biocatalyst. Although evolutionarily selected to 
catalyze elimination, AbyA5 exhibits kinetic parameters for ester 
hydrolysis comparable to naturally evolved acetyl esterases. 
Catalytic multifunctionality is an inherent feature of many 
biocatalysts, however; AbyA5 is unusual in its proficiency in 
performing a secondary non-cognate reaction.[15] Our studies also 
further expand the breadth of transformations catalyzed by α/β-
hydrolase fold enzymes, highlighting the utility of this protein 
scaffold in supporting a diverse array of biocatalytic reactions. 
Finally, given the high degree of sequence identify between 
AbyA5 and acetate eliminating enzymes from other 
spirotetronate/spirotetramate pathways, we conclude that many 
of the key findings reported herein will be directly applicable to 
acetate lyases from other biosynthetic pathways. 
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